Press releases
- Innate Pharma: Clarification Regarding SAR443579 Designation
- Innate Pharma Highlights Abstracts Selected for EHA 2024 Congress
- Innate Pharma Reports First Quarter 2024 Business Update and Financial Results
- Innate Pharma Announces Conference Call and Webcast for Q1 2024 Business Update
- Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024
- Innate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients
- Innate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate
- Innate Pharma Announces Its Participation in Upcoming Investor Conference
- Innate Pharma Files Its 2023 Universal Registration Document (Document d’enregistrement Universel) and 2023 Annual Report on Form 20-F
- Innate Pharma Reports Full Year 2023 Financial Results and Business Update
More ▼
Key statistics
On Monday, Innate Pharma SA (IPHYF:PKC) closed at 2.20, 3.29% above its 52-week low of 2.13, set on May 03, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 2.20 |
Average volume | -- |
---|---|
Shares outstanding | 80.86m |
Free float | 60.59m |
P/E (TTM) | -- |
Market cap | 206.60m EUR |
EPS (TTM) | -0.0939 EUR |
Data delayed at least 15 minutes, as of May 20 2024 19:18 BST.
More ▼